We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

4 hedge funds and large institutions have $53.5K invested in NeuroSense Therapeutics Warrant in 2022 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1.49% less ownership

Funds ownership: 4.12% → 2.63% (-1.5%)

20% less funds holding

Funds holding: 5 → 4 (-1)

50% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 2

51% less capital invested

Capital invested by funds: $109K → $53.5K (-$55.5K)

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CS
Clear Street
New York
+$74

Top Sellers

Rank Fund Capital Flow
1
WAM
Warberg Asset Management
Illinois
-$563
2
UBS Group
UBS Group
Switzerland
-$293
Name Holding Trade Value Shares
Change 		Change in
Stake
Hudson Bay Capital Management
1
Hudson Bay Capital Management
Connecticut
$30K – – –
WAM
2
Warberg Asset Management
Illinois
$14.4K -$563 -2,232 -3%
CS
3
Clear Street
New York
$9K +$74 +293 +0.5%
UBS Group
4
UBS Group
Switzerland
$128 -$293 -1,160 -59%

NRSNW Hedge Fund Activity: Q4 2022 in Review

4 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2022, worth a combined $53.5K — down 51% from $109K a quarter earlier.

Fund positioning in NRSNW was balanced in Q4 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.

The largest buyer was Clear Street, adding an estimated $74. The largest seller was Warberg Asset Management, cutting an estimated $563.

  • 4 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2022, down from 5 in Q3 2022.
  • Funds reported $53.5K of NeuroSense Therapeutics Warrant stock for Q4 2022, down 51% quarter-over-quarter.
  • 0 funds opened new NeuroSense Therapeutics Warrant positions in Q4 2022 and 0 closed out.
  • The largest NeuroSense Therapeutics Warrant buyer in Q4 2022 was Clear Street, an estimated $74 added.
  • The largest NeuroSense Therapeutics Warrant seller in Q4 2022 was Warberg Asset Management, an estimated $563 sold.

Based on aggregated 13F filings for Q4 2022.